

# Investor Relations 2019

Copyright © VATECH Networks | All Rights Reserved.

This presentation has been prepared by Rayence (hereinafter "the Company), with an aim to promote investors' understanding of the Company. This presentation May not be distributed modified, reproduced in whole or in part.

The accuracy of the 'forward-looking statements' included in this presentation has not been independently verified. The forward-looking statements include projections and outlook of the Company concerning its business status and financial results, and include but not limited to words, such as 'expectation'. 'forecast', 'plan', 'anticipation' or '(E)'. The forward-looking statements are subject to changes in business environment and involve inherent risks and uncertainties.

Future expectations are based on current business environment and the Company's management direction as of the date of presentation. Future projections may differ or change due to changes in business environment or due to strategic changes by the Company,. The contents in this presentation may change with out any prior notification.

None of the Company nor ant of its respective officers assume legal responsibility for any damages or losses that may have occurred from the use of this presentation, including errors and other mistakes that may be included in this presentation

This presentation may not ne reproduced in whole or in part, nor may any of its contents be divulged to any third party, unless prior consent by the Company has been granted

# Contents

I. Company Overview

II. Market Trend & Competitiveness

III. Financial Status

# I. Company Overview



1-1. Corporate Information

1-2. Company History

1-3. Business Area


1-4. Products & Applications

### Korea No.1 Digital X-ray Detector Maker

#### Corporate Data



회사명	(주)레이언스
설립일 / 상장일	'11. 05. 02 / '16. 04. 11
대표이사	김태우
임직원수	224명
자본금	8,296백만원
주요제품	TFT-CMOS 디텍터, I/O 센서 등
본사위치	경기도 화성시 삼성1로 1길 14



[2018.12.31]

구분	주식수	비율(%)
대주주외 특수관계자	10,777,455	65.0%
자사주	854,574	5.2%
외국인	997,254	6.0%
기타 국내 기관 및 개인투자자	3,961,731	23.8%
합계	16,591,014	100.0%

#### rayence investor relations 2019


### 2019년 신수종사업 개발을 통해 글로벌 DR 제조사로 도약



## 기술 내재화 및 수직 계열화로 원천 기술 및 원가 경쟁력 확보

[Digital X-ray System]


[Technologies of Digital X-ray Detector]



#### rayence

	TFT Detect	or	CMOST	Domestic Market				
	(박막트렌지스터 기법		CMOS Detector No.1 / Only 1 (Crystalline 실리콘 웨이퍼 기반 디텍터)					
Strengths	Very Large Panel / Simple / Econo	omical	High Speed & Resolution / N	No Image Lag				
Weaknesses	Low Resolution / Image Lag / Slow	W	Limited Size (Needs Sensor	tiling) / Expensive				
Products								
Applications								
Medical	General Radiography	Mobile X-Ray	Surgical/c-arm	Mammography				
Dental			Dental 2D/3D	Dental IOS				
Industrial	NDT Portable	Security/EOD	Automatic X-ray Inspection	) n(SEMI/Battery/Die-Casting)				
VET	Small Animal	Equine	VET					

# II. Market Trend & Competitiveness




rayence

### 2022년까지 글로벌 X-Ray 디텍터 시장의 연평균성장률 5.6%


[글로벌 X-RAY 디텍서 시장 TOTAL ]

[BY APPLICATION]



### 2-1. Our Sustainable Market

rayence




	Film	CR	DR
Time for getting image	Slow	Normal	Fast
Image processing	Х	0	0
Dynamic Range	Narrow	Wide	Wide
Cost (Invest side)	Low	Normal	High
Cost (Managing side)	High	Normal	Low



# 신수종 전략 사업을 통한 지속 성장동력 마련

Medical	Dental	Industrial
고부가가치 CMOS 라인업 확대	EOS/IOS 센서 신규 고객 발굴	신제품 개발 및 시장침투
1. CMOS 의료 특화 시장 진출	1. CMOS 디텍터 바텍외 고객 확대	1. Electronic M/S 1위 달성
- 수술용 C-arm 시장 신규 진입 <sup>[c-arm]</sup> '18y → '20y Global 수술용 c-arm Market Forecasting	- 중국 신규 Dental System社 확보 완료 (CMOS 디텍터 중국내 M/S 1위 목표)	- Tier1 업체 High Class 반도체 검사 진입 (고감도/고해상도/고관전압)
(483m\$ → 507m\$)	- 중국외 신규 Digital Sys.社 발굴	- TDI 제품 출시
- Mammo Retrofit 시장 개척 [Mammo]	ODM	(2차전지 및 Mobile 검사 진입)
* '18y $\rightarrow$ '20y Global Mammo Market Forecasting (1,207m\$ $\rightarrow$ 1,338m\$)	Vatech	
2. 고부가가치 Medical TFT 사업 추진	2. Global IOS 시장 지배력 강화	[ <sup>[]</sup> ] <sup>[]</sup> [LED]
2. 고구가가가 Wedical TFT 자급 구전     - 방사선 치료기기     [Radiotherapy]     (Radiotherapy)     신시장 개척	- Global Big 2 Market (USA&China) 공략 강화	<b>2. Die casting 용 CMOS 시장 개척</b> - 3D CT Full Size lineup 확보 - 2D 검사 시장 확판
	- 유럽 지역 Local System사 등 Major 경쟁사 시장 침투	3. New Application 개발 및 시장 진입
3. OSKO를 통한 중남미 Retrofit 시장 공략	"The world's first bendable IOS"	
- 현지 생산 기반 중남미 Medical시장 공략	2mm bendable	[Food] [Aerospace]


# III. Financial Status





#### 3-1. Business Performance

rayence



rayence

(단위:백만원,%)

#### 3Q19 매출액**32,098 백만원 (3***분기 기준 최대 매출액***)** 영업이익 **5,827 백만원**, 당기순이익 **4,783 백만원**

3Q19 매출액	
· 매출액 32,098백만원, 영업이익 5,827백만원 - 매출액 +2,444백만원, 전년동기 대비 +8.2% → 3분기 기준 최대 매출액	
· Medical 매출액 전년동기 대비 +27.5%	매클
· Dental 매출액 전년동기 대비 +6.8% - IOS 매출액 전년동기 대비 +244.5%	매클
* Sales Breakdown	매클
- TFT : 150억원 (전년동기 대비 +18.5%)	
- CMOS : 103억원 (전년동기 대비 -21.2%)	

- CMOS : 103억원 (선년동기 내비 -21.2%)

- IOS : 62억원 (전년동기 대비 +244.5%)
- Other: 6억원 (전년동기 대비 -43.1%)

YoY 구분 3Q18 3Q19 (%) 춬액 32,098 100.0% 29,655 100.0% 8.2% 출원가 59.7% 18,036 60.8% 19,169 6.3% 출총이익 12,929 40.3% 11,618 39.2% 11.3% 판관비 7,102 22.1% 5,968 20.1% 19.0% 영업이익 18.2% 5,827 5,651 19.1% 3.1% 당기순이익 4,783 14.9% 4,425 14.9% 8.1%

## 3-3. Sales Breakdown

#### (단위 : 백만원, %)

Biz		FY 2017							FY 2018						FY 2019			
	1Q	2Q	3Q	4Q	Annual	%	1Q	2Q	3Q	4Q	Annual	%	1Q	2Q	3Q	1~3Q	%	
TFT	11,325	12,496	14,932	13,350	52,103	<b>48.9</b> %	12,207	14,532	12,617	14,402	53,757	46.2%	11,124	14,363	14,953	40,440	43.4%	
CMOS	7,959	8,066	9,202	7,335	32,563	<b>30.6</b> %	10,027	11,733	14,092	6,292	42,143	36.2%	10,501	10,875	10,262	31,638	34.0%	
10	4,658	5,468	4,686	4,573	19,385	18.2%	5,537	3,536	1,893	5,717	16,682	14.3%	4,267	6,442	6,236	16,945	18.2%	
Others	626	566	639	636	2,467	2.3%	703	949	1,053	1,101	3,807	3.3%	2,413	1,014	647	4,073	4.4%	
Total	24,568	26,596	29,460	25,894	106,518	100.0%	28,473	30,749	29,655	27,512	116,389	100.0%	28,304	32,694	32,098	93,096	100.0%	

#### (단위 : 백만원, %)

		FY 2017							FY 2018						FY 2019			
Арр.	1Q	2Q	3Q	4Q	Annual	%	1Q	2Q	3Q	4Q	Annual	%	1Q	2Q	3Q	1~3Q	%	
Medical	9,909	11,766	12,260	12,821	46,755	<b>43.9</b> %	10,948	11,148	9,274	10,252	41,623	35.8%	10,627	11,266	11,821	33,714	36.2%	
Dental	10,713	10,978	12,214	9,756	43,661	41.0%	13,792	13,213	14,044	10,156	51,205	44.0%	13,053	15,893	14,994	43,940	47.2%	
Industrial	2,073	2,067	4,151	2,028	10,319	9.7%	1,596	3,174	3,216	3,372	11,357	<b>9.8</b> %	1,669	3,259	2,373	7,301	<b>7.8</b> %	
VET	1,873	1,785	836	1,288	5,782	5.4%	2,137	3,214	3,121	3,732	12,204	10.5%	2,956	2,275	2,910	8,141	8.7%	
Total	24,568	26,596	29,460	25,894	106,518	100.0%	28,473	30,749	29,655	27,512	116,389	100.0%	28,304	32,694	32,908	93,096	100.0%	

### 3-3. Sales Breakdown @ Region

#### rayence

# Asia Sales was increased 3.8%

· Dental IO's sales was increased yoy

#### ► E.U

- Sales was increased yoy 104%


· Medical sales was increased yoy

#### N. America

- Sales was increased yoy 4.4%

#### MENA / Africa, Oceania

- Sales was decreased yoy 27%, 35%



(단위 : 백만원, %)

Deview		FY 2017							FY 2018						FY 2019			
Region	1Q	2Q	3Q	4Q	Annual	%	1Q	2Q	3Q	4Q	Annual	%	1Q	2Q	3Q	1~3Q	%	
N. America	6,991	6,934	10,540	7,584	32,049	30.1%	7,383	9,129	5,733	5,320	27,566	23.7%	6,505	7,378	5,984	19,867	21.3%	
Asia	15,766	17,964	17,592	16,140	67,461	63.3%	18,987	19,256	21,085	19,560	78,889	67.8%	19,521	22,518	21,883	63,922	68.7%	
E.U	1,644	1,545	981	1,690	5,861	5.5%	1,987	2,152	1,659	1,539	7,338	6.3%	1,853	1,905	3,388	7,146	7.7%	
Africa/ MENA	95	17	184	428	723	0.7%	94	94	1,010	936	2,134	1.8%	334	794	733	1,861	2.0%	
Oceania	74	134	163	52	423	0.4%	22	117	168	156	463	0.4%	91	99	110	300	0.3%	
Total	24,568	26,596	29,460	25,894	106,518	100.0%	28,473	30,749	29,655	27,512	116,389	100.0%	28,304	32,694	32,098	93,096	100.0%	



경기 화성시 삼성1로1길 14 (18449) T: 031-8015-6420 www.rayence.com 14, Samsung 1-ro 1-gil, Hwaseong-si, Gyeonggi-do 18449, Korea

Copyright © VATECH Networks | All Rights Reserved.

												(단위	: 백만원, %)
구분	3Q	18	2Q	19	3Q	19	QoQ (%)	YoY (%)	1~3Q	2018	1~3Q	2019	YoY (%)
Sales	29,655	100.0%	30,749	100.0%	32,098	100.0%	4.4%	8.2%	88,877	100.0%	93,096	100.0%	4.7%
COGS	18,036	60.8%	18,771	61.0%	19,169	59.7%	2.1%	6.3%	54,404	61.2%	55,064	59.1%	1.2%
Gross Profit	11,618	39.2%	11,978	39.0%	12,929	40.3%	7.9%	11.3%	34,474	38.8%	38,032	69.1%	10.3%
SG&A	5,968	20.1%	5,603	18.2%	7,102	22.1%	26.8%	19.0%	17,268	19.4%	20,872	54.9%	20.9%
Operating Income	5,651	19.1%	6,375	20.7%	5,827	18.2%	-8.6%	3.1%	17,206	19.4%	17,159	82.2%	-0.3%
Other gains	33	0.1%	462	1.5%	326	1.0%	-29.4%	900.1%	422	0.5%	1,336	141.2%	216.6%
Finance income	126	0.4%	343	1.1%	315	1.0%	-8.2%	150.1%	791	0.9%	1,245	405.6%	57.3%
Income Before Tax	5,809	19.6%	7,180	23.3%	6,468	20.1%	-9.9%	11.3%	18,419	20.7%	19,740	1585.8%	7.2%
Income Tax Expense	1,384	4.7%	1,602	5.2%	1,685	5.2%	5.2%	21.7%	3,836	4.3%	5,509	27.9%	43.6%
Net Income	4,425	14.9%	5,578	18.1%	4,783	14.9%	-14.3%	8.1%	14,583	16.4%	14,231	258.3%	-2.4%

# Appendix 2. Balance Sheet Summary



				(KRW Million)
Account	FY 3Q 2019	FY 2018	FY 2017	FY 2016
Current assets	162,293	147,450	140,585	136,127
Cash and cash equivalents	21,159	25,980	20,740	9,093
Short-term deposits not classified as cash equivalents	61,700	60,290	69,406	76,013
Short-term trade Receivable	45,665	25,972	18,253	21,841
Inventories	28,988	30,723	27,316	24,926
Other current assets	4,781	4,485	4,871	4,253
Non-current assets	64,644	53,682	55,865	54,231
Property, plant and equipment	37,583	32,693	34,370	34,506
Intangible assets	22,657	19,248	20,414	18,299
Other non-current assets	4,404	1,741	1,080	1,427
Total assets	226,937	201,132	196,450	190,358
Current liabilities	22,277	16,935	17,584	20,514
Short-term trade Payables	7,179	5,935	6,540	7,986
other current payables	3,293	2,510	3,755	3,906
Short-term borrowings	5,434	1,617	5,324	5,710
Other current liabilities	6,371	6,873	1,964	2,911
Non-current liabilities	9,436	1,870	1,884	3,796
Long-term borrowings, gross	-	-	472	2,082
Post-employment benefit obligations	1,301	387	828	1,472
Other Non-current liabilities	8,135	1,483	584	242
Total liabilities	31,713	18,805	19,467	24,310
Equity				
Equity attributable to owners of parent	194,957	181,864	176,641	165,421
Issued capital	8,296	8,296	8,296	8,296
Share premium	107,298	107,298	107,298	107,298
Elements of other stockholder's equity	(15,616)	(15,404)	(6,677)	(4,532)
Other Comprehensive income/loss accumulated amount	37	104	24	381
Retained earnings	94,943	81,571	67,700	53,979
Non-controlling interests	267	463	343	627
Total equity	195,224	182,327	176,983	166,048
Total equity and liabilities	226,937	201,132	196,450	190,358



